Finotello R, Vasconi M E, Sabattini S, Agnoli C, Giacoboni C, Annoni M, Dentini A, Bettini G, Guazzi P, Stefanello D, Bottero E, Mesto P, Marinelli R, De Feo C, Marconato L
Small Animal Teaching Hospital, School of Veterinary Sciences, University of Liverpool, Neston, UK.
Centro Veterinario Torinese, Torino, Italy.
Vet Comp Oncol. 2018 Mar;16(1):159-166. doi: 10.1111/vco.12325. Epub 2017 May 29.
Feline large granular lymphocyte (LGL) lymphoma is an uncommon subtype of lymphoma characterized by a grave prognosis and scarce response to chemotherapy. There are limited reports on clinico-pathological and prognostic factors. One-hundred and 9 cats with newly diagnosed LGL lymphoma that underwent initial staging (including hematology, serum biochemistry, thoracic radiographs and abdominal ultrasound), and followed-up were retrospectively evaluated. LGL lymphoma was localized within the gastrointestinal tract with or without extra-intestinal involvement in 91.7% of the cases, and at extra-gastrointestinal sites in 8.3%. Symptoms were frequent. Anemia (31.2%) and neutrophilia (26.6%) were commonly observed, and 14 (12.8%) cats had neoplastic circulating cells. Frequent biochemistry abnormalities included elevated ALT (39.4%) and hypoalbuminemia (28.4%). Twenty (54.1%) of 37 cats had elevated serum LDH. Treatment varied among cats, and included surgery (11%), chemotherapy (23%), corticosteroids (38.5%) and no treatment (27.5%). Median time to progression (MTTP) was 5 days, and median survival time (MST) 21 days. MST was significantly shorter in the case of substage b, circulating neoplastic cells, lack of chemotherapy administration, and lack of treatment response. A small subset of cats (7.3%) survived more than 6 months, suggesting that a more favorable clinical course can be found among LGL lymphoma patients.
猫大颗粒淋巴细胞（LGL）淋巴瘤是一种罕见的淋巴瘤亚型，其预后严重，对化疗反应不佳。关于临床病理和预后因素的报道有限。对190只新诊断为LGL淋巴瘤并接受初始分期（包括血液学、血清生化、胸部X光片和腹部超声）及随访的猫进行了回顾性评估。91.7%的病例中，LGL淋巴瘤局限于胃肠道，伴或不伴有肠外受累，8.3%的病例位于胃肠道外部位。症状常见。常见贫血（31.2%）和中性粒细胞增多（26.6%），14只（12.8%）猫有肿瘤循环细胞。常见的生化异常包括ALT升高（39.4%）和低白蛋白血症（28.4%）。37只猫中有20只（54.1%）血清乳酸脱氢酶升高。猫的治疗方法各不相同，包括手术（11%）、化疗（23%）、皮质类固醇（38.5%）和未治疗（27.5%）。中位进展时间（MTTP）为5天，中位生存时间（MST）为21天。在分期为b、有肿瘤循环细胞、未进行化疗以及无治疗反应的情况下，MST显著缩短。一小部分猫（7.3%）存活超过6个月，这表明LGL淋巴瘤患者中可能存在更有利的临床病程。
